1. Academic Validation
  2. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes

Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes

  • J Med Chem. 2013 Jun 27;56(12):5094-114. doi: 10.1021/jm400459m.
Yulin Wu 1 Christopher J Aquino David J Cowan Don L Anderson Jeff L Ambroso Michael J Bishop Eric E Boros Lihong Chen Alan Cunningham Robert L Dobbins Paul L Feldman Lindsey T Harston Istvan W Kaldor Ryan Klein Xi Liang Maggie S McIntyre Christine L Merrill Kristin M Patterson Judith S Prescott John S Ray Shane G Roller Xiaozhou Yao Andrew Young Josephine Yuen Jon L Collins
Affiliations

Affiliation

  • 1 GlaxoSmithKline Research & Development, Five Moore Drive, Research Triangle Park, North Carolina 27709, USA.
Abstract

The Apical Sodium-Dependent Bile Acid Transporter (ASBT) transports bile salts from the lumen of the gastrointestinal (GI) tract to the liver via the portal vein. Multiple pharmaceutical companies have exploited the physiological link between ASBT and hepatic Cholesterol metabolism, which led to the clinical investigation of ASBT inhibitors as lipid-lowering agents. While modest lipid effects were demonstrated, the potential utility of ASBT inhibitors for treatment of type 2 diabetes has been relatively unexplored. We initiated a lead optimization effort that focused on the identification of a potent, nonabsorbable ASBT inhibitor starting from the first-generation inhibitor 264W94 (1). Extensive SAR studies culminated in the discovery of GSK2330672 (56) as a highly potent, nonabsorbable ASBT inhibitor which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes.

Figures
Products